Functionalized Graphene Quantum Dot Interfaced Electrochemical Detection of Cardiac Troponin I: An Antibody Free Approach

Muthaiyan Lakshmanakumar¹,², Noel Nesakumar², Swaminathan Sethuraman¹,³, K. S. Rajan¹,³, Uma Maheswari Krishnan¹,³,⁴ & John Bosco Balaguru Rayappan¹,²*

According to the World Health Organization (WHO), cardiovascular disease (CVD) is the leading cause of death in the world every year. The design and development of biosensors for the detection of CVD markers could be one of the major contributions of the scientific community to society. In this context, acetic acid functionalized graphene quantum dots (fGQDs) were used as an interface for the electrochemical detection of cardiac Troponin I (cTnI). The interaction of cTnI with fGQDs for the early diagnosis of acute myocardial infarction was investigated using cyclic voltammetry (CV) and amperometry. The carbodiimide conjugation between the N-H group of cTnI and the functionalized COOH group on GQDs enabled the detection of cTnI biomarker. The same sensing mechanism was confirmed using Fourier Transform Infrared Spectrometry (FTIR). The fGQDs modified Au electrode showed remarkable electrocatalytic oxidation of cTnI with good stability and sensitivity over a linear range of 0.17 to 3 ng mL⁻¹ and a low detection limit of 0.02 ng mL⁻¹. Bland-Altman plots substantiate a bias between the intra-/inter-cTnI assay and calibrated cTnI assay with 95% limits of agreement (mean difference ± 1.96 SD). The aim of this study is to describe an innovative method to detect cardiac biomarker cTnI and provide preliminary data on its diagnostic capacity. At the same time, its applicability in clinical setting will have to be validated with a significant number of samples collected from patients.

Acute myocardial infarction (AMI) is one of the leading causes of death in humans. The American Heart Association reported 13.5% of sudden heart-related deaths in the United States in 2018. In this scenario, spontaneous and accurate diagnosis of AMI has garnered attention among research groups. The market for cardiac biomarkers is expected to reach USD 13.3 billion by 2024. Although different cardiac biomarkers are available to detect AMI, such as lactate dehydrogenase (LD), myoglobin (MB), creatine kinase-myoglobin (CK-MB) and C-reactive protein (CRP), they are less specific and sensitive than Cardiac Troponin (cT). Cardiac Troponin I (cTnI) is a “Gold Standard” biomarker for the early diagnosis of AMI because of its high sensitivity and specificity. cTnI is released directly into the blood and its concentration in healthy people is less than 0.4 ng mL⁻¹, while concentrations greater than 2.0 ng mL⁻¹ indicate the presence of AMI. Conventional methods used to detect cTnI are surface plasmon resonance (SPR), chemiluminescence, enzyme-linked immunosorbent assay (ELISA), electrochemical impedimetric, quartz crystal microbalance, colorimetric, fluorescence resonance energy transfer (FRET) and radio-immunnoassay (RIA). But the main disadvantages of these methods include expensive instruments, multistage processing, and long step analysis with low sensitivity.

In this context, electrochemical biosensors with a functionalized interface could be an effective solution for the detection of cTnI. Tungsten trioxide reduced graphene oxide nano-composite matrix was functionalized with amino groups using 3-aminopropyl tri-ethoxy saline, which covalently bonded to anti-cTnI. This immune-sensor showed a sensitivity of 58.24 mA cm⁻² in a linear detection range of 0.01–250 ng mL⁻¹ and remained stable for...
30 days. Similarly, 2-aminobenzyl amine functionalized graphene decorated on interdigitated electrode was fabricated to achieve amine functionalized graphene (f-GN). In order to modify f-GN electrode with monoclonal anti-cTnI, Schiff’s reaction was used. A wide linear range of cTnI detection ranges from 0.01 to 1 ng mL$^{-1}$ with a limit of detection (LOD) of 0.01 ng mL$^{-1}$ was reported. Bhatnagara et al. have reported amine functionalized graphene quantum dots (afGQDs) bio-conjugated with antibody anti-cTnI to detect cTnI in the blood. However, these functionalized interface-based biosensors use both antigens and antibodies which have several drawbacks, such as low recovery, efficiency, loading, high antibody production costs and lower stability at maximum temperature. Hence, functionalized electrodes without antibody could be a better method for detecting cTnI in terms of the cost, stability and shelf life of the sensor.

Few antibody free approaches, such as the detection of bacteria using quantum dots-based barcode assay and detection of phosphor proteins using platinum and carbon dot hybrid nanomaterials have been reported in the literature. Similarly, in the present work, we have developed an anti-cTnI free electrochemical biosensor with acetic acid functionalized graphene quantum dots interface for early diagnosis of AMI. Since the functionalized GQDs have a high surface area, π-π conjugation, surface grafting and edge plane groups such as carboxyl groups and hydroxyl groups, they exhibit associative interactions with biological moieties. In the present work, fGQDs are used as catalytic signal transducer and carbodiimide conjugation between fGQDs and cTnI forms the basis for cTnI detection. The theoretically elaborated mechanism of associative interactions, as well as stoichiometric reactions of amines on activated carboxylic acid by in situ generated salts and experimental evidence on carboxylic acid and amine interactions induced by 9-silafluorenyl dichlorides as peptide coupling mediator with minimal wastage served as our motivation to develop an electrochemical biosensor with acetic acid functionalized GQDs for the detection of cTnI by enabling the interaction between carboxylic and amide groups of acetic acid and cTnI, respectively.

Results and Discussion

Characterization of fGQDs. Figure 1(a) shows the HR-TEM image of the as-prepared fGQDs. Figure 1(b,c) shows the presence of nearly mono-disperse fGQDs of 2–4 nm and inter-planar spacing fringes of 0.27 nm. The Selected Area Electron Diffraction (SAED) pattern of as-prepared fGQDs (Fig. 1(d)) reveals a hexagonal lattice structure with d spacing of 0.2 nm. The crystalline nature of the sample confirms the absence of carbon quantum dots that are amorphous in nature. The hexagonal lattice structure is typical of graphene quantum dots that have also been reported in earlier work. Figure 1(e) shows the Raman spectra of fGQDs and GQDs for the analysis of disorderliness and defects in samples. The two spectra reveal a peak at 1355 cm$^{-1}$ (D band) due
to the disorder-induced scattering confirming the imperfections in the carbon sp² network induced by sp³ bonded atoms. The intensity of the D-band is higher in the fGQD sample than in the GQD, indicating a higher degree of disorder owing to the introduction of functional groups in the carbon network. The occurrence of a sharp peak at 1566 cm⁻¹ (G band) corresponding to the E₂g vibration mode of sp² carbon atoms in the 2D hexagonal lattice is also observed in the Raman spectra of GQD and fGQD. The I_D/I_G ratio is 0.4 and 0.8 for GQDs and fGQDs, respectively, which is higher than that of pure graphite (~0.1)32,33. It is likely that the higher I_D/I_G ratio for fGQD is due to increase in number of defects34,35. The 2D band appears around 2690 cm⁻¹ in the Raman spectra of both samples. The 2D band for pristine GQD is a sharp peak with relatively higher intensity that its counterpart with a multiplet of low intensity suggesting the presence of additional layers in fGQD due to functional groups on the surface36,37.

Electrochemical studies. Cyclic voltammetry (CV) studies were carried out using GQDs, fGQDs, cTnI/GQDs and cTnI/fGQDs modified Au working electrodes (Fig. 2(a)) in 0.1 M NaCl solution. No redox peak was observed for the Au/GQD electrode, whereas the Au/fGQD electrode had an anodic peak at -0.2 V, indicating the electrocatalytic property of the immobilized fGQDs. The catalytic properties of fGQDs have been well-documented in the literature23,24. In the presence of cTnI, twin anodic peaks at 460 and 623 mV were observed in the Au/fGQD electrode (Fig. 2(b)). The occurrence of these peaks may be explained based on the amino acid residues in the cTnI sequence and associative interactions existing between the amide functionalities of cTnI, as well as the hydrogen bonding interactions of the peptide with the aqueous electrolyte.

The Au-GQD electrode in comparison also shows a similar pattern of peaks but with lower intensity and at a lower potential. Cardiac troponin I is a 210 amino acid protein containing approximately 49% charged amino acids (glutamate, aspartate, lysine, arginine or histidine) and 11% of hydroxyl group containing amino acids (serine, threonine, tyrosine) and, hence, it can interact effectively through hydrogen bonding interactions with the functionalized GQDs more effectively that with a GQD. As a result, greater retention of cTnI is achieved on fGQD through the covalent interactions when compared to GQD. The presence of charged amino acid residues in cTnI contributes to the higher current, whereas the positive shift in the peak potentials on fGQD can occur due to the hydrogen bonding interactions between the peptide and fGQD. The FT-IR spectrum of cTnI (Fig. 2(c)) reveals a broad band centred at 3275 cm⁻¹ due to the –O-H and –N-H stretching vibrations. The broad band suggests the presence of extensive hydrogen bonding. The amide carbonyl stretch appears prominently at 1638 cm⁻¹. The FTIR spectrum of cTnI incorporated fGQD shows a broad vibration band due to –O-H and –N-H stretching vibrations of the protein, while the carboxylic acid functionalization of the fGQD is discernible as a shoulder at 1715 cm⁻¹. The schematic representation of the mechanism of carbodiimide conjugation between peptide chains and water molecules in the electrolyte is shown in Fig. S139.

The cyclic voltammogram of Au/fGQDs electrode for different concentrations of cTnI was recorded at an optimized scan rate of 0.01 V s⁻¹. The oxidation peak currents (I_p1 and I_p2) were found to increase with increasing cTnI concentration from 0.17 to 3.0 ng mL⁻¹ (Fig. 3(a)). The low detection limit (LOD) was found to be 0.02 ng mL⁻¹ for I_p1 at 460 mV, which is attributed to the hydrogen bonding between the amide and fGQD and the additional shoulder anodic peak I_p2 corresponds to C=O–H–O hydrogen bonding between amide-water at 623 mV. Johansson et al. have theoretically reported that "amide-amide hydrogen bonding is stronger than amide-water bonding"40. Both the calibration plots (I_p1 and I_p2) exhibited a linear relationship between various
concentrations of cTnI. The observed anodic oxidation peak current confirmed the surface-controlled process ($R^2 = 0.99$) (Fig. S2(a,b)) and amperometry response was observed for different cTnI concentrations (0.17 to 3.0 ng mL$^{-1}$) at 460 mV. A response time of 10 s was noted and the current attained a steady state, as shown in Fig. 3(b). To verify the anti-interference ability of the sensor, the CV response was recorded in the presence of another protein trypsin and was shown in Fig. 3(c). Twin peaks similar to those observed for cTnI was observed for trypsin but at different potentials of 140 and 300 mV and with reduced magnitude. Trypsin contains 240 amino acid residues of which about 18% are charged (glutamate, aspartate, lysine, arginine or histidine) and 16% are hydroxyl containing amino acids. This suggests that the amount of trypsin retained on the surface of fGQD will be lower owing to lesser non-convalent interactions. In addition, the lower number of charges on the trypsin reduces the magnitude of current recorded at the Au/fGQDs surface. This study clearly confirmed that cTnI can be detected without antibody at the specific potential of 460 mV using Au/fGQDs electrode. In order to confirm reproducibility, sensing performance of the fabricated Au/fGQDs electrodes was studied and a relative standard deviation (RSD) of 3.1% was obtained as shown in Fig. 3(d). In order to assess the bias between the mean differences and to estimate an agreement interval, within which 95% of the differences between the intra-/inter-cTnI assay and calibrated cTnI assay falls, Bland and Altman analysis is performed. As can be seen from Fig. 4(a,b), the maximum allowed differences between TEST1 and TEST2, TEST3 were within the limit of agreement, suggesting that the proposed cTnI assay is in agreement with intra- and inter-cTnI assay standards.

To the best our knowledge, there are no articles on antibody-free electrochemical detection of cTnI. However, there is a unique report that uses the surface plasmon resonance technique for the detection of cTnT, also a biomarker for Acute Myocardial Infarction (AMI) in which Palladino et al., employed the epitope imprinted surface towards antibody free point of care testing for AMI. They reported a LOD of 15.4 nM, which is almost $10^3$ times higher than the LOD obtained by fGQDs modified Au electrode (0.02 ng mL$^{-1}$). In this context, the proposed electrochemical detection method can pave the ways for affordable real-time testing with an effective, antibody free tool for inexpensive point-of-care devices to detect the cardiac biomarkers assays.

**Conclusion**

The diagnostic capacity of an antibody-free fGQDs-interfaced electrochemical biosensor for the detection of cTnI has been reported. The hydrogen bonding interactions mediated by the carboxylic group in fGQDs played an important role in the detection of cTnI. The developed Au/fGQDs sensor displayed sensitivity over a linear range of 0.17–3 ng mL$^{-1}$ and a low detection limit of 0.02 ng mL$^{-1}$. Bland and Altman analysis was carried out for the
proposed cTnI assay showed 95% agreement between the intra-/inter-cTnI assay and calibrated cTnI assay. Even though this antibody-free biosensor was sufficiently sensitive and stable in detecting cTnI, an extensive validation on a pre-determined number of patients are required before its use can be considered in a clinical setting.

**Experimental Materials.** Human heart cTnI protein reagent, trypsin and nafion were procured from Sigma-Aldrich, India. Graphite was purchased from Alfa Aesar, India. Sodium chloride, sodium nitrate, sulphuric acid, hydrazine monohydrate, potassium permanganate, hydrogen peroxide, dimethylformamide and acetic acid were procured from Merck, India.

**Apparatus.** The structural morphology of fGQDs was studied using a field emission transmission electron microscope (FE-TEM)(JSM 2100 F, JEOL, Japan). The degree of orderliness/disorderliness and defects of fGQDs were identified using Raman spectrometer (Horiba Xplora, Japan). The interaction between immobilized fGQDs and human cTnI was evaluated using attenuated total reflectance (ATR) mode in the Fourier Transform Infrared (FT-IR) spectrometer (Alpha T, Bruker, Germany) in the spectral range of 1300–3600 cm⁻¹ with a spectral resolution of 8 cm⁻¹. Cyclic voltammetry and amperometry measurements were carried out using CH600C electrochemical workstation (CH Instruments Inc., USA) with CH600C software. Electrochemical experiments were conducted using three electrode systems with platinum wire as the auxiliary electrode, Ag/AgCl saturated in 0.1 M KCl as the reference electrode, and fGQD modified gold electrode (fGQD/Au) as the working electrode. All experiments were performed at ambient temperature (300 K).

**Synthesis of fGQDs.** Graphene Oxide (GO) was synthesized using the modified Hummer’s method. 1 g graphite and 0.8 g sodium nitrate were added to 30 mL of sulphuric acid and continuously stirred in an ice bath for 4 h. Subsequently, 4 g of potassium permanganate was slowly mixed with the solution and stirred at room temperature for 1 h. 100 mL of deionized water was added to the solution and warmed at 310 K for 1 h. The further reaction was terminated using (10 mL) 30 w/v% of hydrogen peroxide. The formation of GO was indicated by a sudden transformation of the black coloured solution into brownish colour. The prepared GO was washed several times with 5 w/v% of HCl and filtered GO was dried for 24 h. For the synthesis of GQDs, 1 g of GO was added to 100 µL dimethylformamide, 1µL hydrazine monohydrate and stirred at room temperature for 12 h. The solution was ultrasonicated for 24 h and then stirred for 1 h at 353 K. Functionalized graphene quantum dots (fGQDs) were prepared by adding 10 mg of GQDs with 20 w/v% of acetic acid, 0.5% of nafion (100 µL) and ultrasonicated for 3 h at 353 K.

**Fabrication of Au/fGQDs Electrode.** The electrode kinetics was improved by removing the oxide layer and the contaminants on the surface of Au working electrode. 0.05 µm alumina powder was used to polish the electrode surface and pretreated by soaking in 1.0 M KOH and 10 w/v% of HNO₃ for 15–20 min. Later, as-prepared fGQDs were ultrasonicated for 2 h and 3 µL of fGQDs were drop casted on the surface of the bare Au working electrode. Finally, the fabricated Au/fGQDs working electrode was dried at room temperature for 3 h.

Received: 16 May 2019; Accepted: 29 October 2019; Published online: 22 November 2019

**References**

1. Benjamin, E. J. *et al.* Heart disease and stroke statistics - 2018 update: A report from the American Heart Association. *Circulation* 137 (2018).
2. Africa, S., GmbH, H., Diagnostics, R., Coulter, B. & Scientific, T. F. Cardiac Biomarkers Market To Reach $ 13. 3 Billion By 2024. 1–5 (2018).
3. Di Serio, F. et al. Point-of-care cardiac markers: Clinical impact of the troponin 99 TH percentile cutoff and clinical utility of the myoglobin measurement in the early management of chest pain patients in a low to intermediate acute coronary syndrome risk population admitt. *Point Care* **6**, 183–186 (2007).

4. Boeckel, J. N. et al. Adjusted Troponin i for Improved Evaluation of Patients with Chest Pain. *Sci. Rep.* **8**, 1–9 (2018).

5. Hasic, S., Kiseliakovici, E., Jadic, R., Radovanovic, J. & Winterhalter-Jadic, M. Cardiac troponin I: the gold standard in acute myocardial infarction diagnosis. *Bom. J. Basic Med. Sci.* **3**, 41 (2009).

6. Varga, A., Schober, K. E., Walker, W. L., Lakritz, J. & Rings, D. M. Validation of a Commercially Available Immunoassay for the Measurement of Bovine Cardiac Troponin I. **359–365** (2009).

7. Periyakaruppan, A., Gandhiraman, R. P., Meyyappan, M. & Koehne, J. E. Label-free detection of cardiac troponin-I using carbon nanofiber based nanoelectrode arrays. *Anal. Chem.* **85**, 3858–3863 (2013).

8. Kow, Y. C. et al. Development of a surface plasmon resonance-based immunosensor for the rapid detection of cardiac troponin I. *Biosens. Bioelectron.* **33**, 921–927 (2011).

9. Rezaee, M. A., Rasaei, M. J. & Mohammadnejad, J. Selection of specific inhibitor peptides in enzyme-linked immunosorbent assay (ELISA) of cardiac troponin I using human-minor epitope as competitor. *J. Immunol. Immunother.* **38**, 72–81 (2017).

10. Wu, J., Crocke, D. M., West, A. C. & Banta, S. Development of a troponin i biosensor using a peptide obtained through phage display. *Anal. Chem.* **82**, 8235–8243 (2010).

11. Guo, H. et al. Development of a Low Density Colorimetric Protein Array for Cardiac Troponin I Detection. *J. Nanosci. Nanotechnol.* **5**, 2161–2166 (2005).

12. Nandihonda, P. & Heagy, M. D. An abiotic fluorescent probe for cardiac troponin i. *J. Am. Chem. Soc.* **133**, 14972–14974 (2011).

13. Cummins, B., Auckland, M. L., Cummins, P. & Birmingham, P. D. The Diagnosis of Troponin i in Acute Myocardial Infarction. in (1987).

14. Freitas, T. A., Mattos, A. B., Silva, R. V. & Dutra, R. F. Amino-Functionalization of Carbon Nanotubes by Using a Factorial Design: Human Cardiac Troponin T Immunosensing Application. *Biomed. Res. Int.* **2014** (2014).

15. Bakirhan, N. K., Ozcelikay, G. & Ozkan, S. A. Recent progress on the sensitive detection of cardiovascular disease markers by electrochemical-based biosensors. *J. Pharm. Biomed. Anal.* **159**, 406–424 (2018).

16. Kumar, S., Kumar, S., Augustine, S. & Malhotra, B. D. Protein functionalized nanostrucutred zirconia based electrochemical immunosensor for cardiac troponin i detection. *J. Mater. Res.* **32**, 2866–2872 (2017).

17. Sandil, D., Srivastava, S., Malhotra, B. D., Sharma, S. C. & Puri, N. K. Biofunctionalized tungsten trioxide-reduced graphene oxide nanocomposites for sensitive electrochemical immunosensing of cardiac biomarker. *J. Alloys Compd.* **763**, 102–110 (2018).

18. Tuteja, S. K., Kukkar, M., Suri, C. R., Paul, A. K. & Deep, A. One step in-situ synthesis of amine functionalized graphene for immunosensing of cardiac marker Ctnt. * Biosens. Bioelectron.* **66**, 12–135 (2015).

19. Bhatnagar, D., Kaur, I. & Kumar, A. Ultrasonic sensitive cardiac troponin I antibody based nanohybrid sensor for rapid detection of human heart attack. *Int. J. Biol. Macromol.* **95**, 505–510 (2017).

20. Jo, H. et al. Electrochemical Apatensor for Cardiac Troponin I for the Early Diagnosis of Acute Myocardial Infarction. *Anal. Chem.* **87**, 9869–9875 (2015).

21. Cihalova, K. et al. Antibody-free detection of infectious bacteria using quantum dots-based barcode assay. *J. Pharm. Biomed. Anal.* **134**, 325–332 (2017).

22. Wang, Y., Qi, W. & Song, Y. Antibody-free detection of protein phosphorylation using intrinsic peroxidase-like activity of platinum/ carbon dot hybrid nanoparticles. *Chem. Commun.* **52**, 7994–7997 (2016).

23. Yola, M. L. & Aatar, N. Functionalized Graphene Quantum Dots with Bi-Metallic Nanoparticles Composite: Sensor Application for Simultaneous Determination of Ascorbic Acid, Uric Acid, and Tryptophan. *J. Electrochem. Soc.* **163**, B718–B725 (2016).

24. Ding, Z., Xiao, Z., Xie, Z. & Liu, J. Functionalized graphene quantum dots as a novel cathode interlayer of polymer solar cells. *J. Mater. Chem. A* **4**, 2413–2418 (2016).

25. Jiang, Y. Y., Zhu, L., Liang, Y., Man, X. & Bi, S. Mechanism of Amide Bond Formation from Carboxylic Acids and Amines Promoted by 9-Silafluorenyl Dichloride Derivatives. *J. Org. Chem.* **82**, 9087–9096 (2017).

26. Aspin, S. J., Taillendaud, S., Cy, P. & Chariette, A. B. 9-Silafluorenyl Dichlorides as Chemically Ligating Coupling Agents and Their Application in Peptide Synthesis. *Angew. Chemie - Int. Ed.* **55**, 13833–13837 (2016).

27. Jursic, J. B. S. & Zdravkovski, Z. A simple preparation of amides from acids and amines by heating of their mixture. *Synth. Commun.* **23**, 2761–2770 (1993).

28. Siddique, A. B., Pramanick, A. K., Chatterjee, S. & Ray, M. Amorphous Carbon Dots and their Remarkable Ability to Detect 2,4,6-Trinitrophenol. *Sci. Rep.*, https://doi.org/10.1038/s41598-018-28021-9 (2018).

29. Kelarakis, A. From highly graphic to amorphous carbon dots: A critical review. *MRS Energy Sustain.*, https://doi.org/10.1557/ mre.2014.7 (2014).

30. Kim, S.-G. et al. Size Fractionation of fluorescent Graphene Quantum Dots using a Cross-Flow Membrane Filtration System. https://doi.org/10.3390/nano8110959.

31. Liu, Q. et al. Green Preparation of High Yield Fluorescent Graphene Quantum Dots from Coal-Tar-Pitch by Mild Oxidation, https://doi.org/10.3390/nano8100844 (2018).

32. Peng, I. et al. Graphene quantum dots derived from carbon fibers. *Nano Lett.*, https://doi.org/10.1021/110238972 (2012).

33. Muzyka, R., Drewniak, S., Pustelny, T., Chrubasik, M. & Gryglewicz, G. Characterization of graphite oxide and reduced graphene oxide obtained from different graphite precursors and oxidized by different methods using Raman spectroscopy. *Materials (Basel)*, https://doi.org/10.3390/ma11071050 (2018).

34. Häger, S., Dotzor, C. & Hirsch, A. Visualization of defect densities in reduced graphene oxide. *Carbon N. Y.*, https://doi.org/10.1016/j. carbon.2012.03.039 (2012).

35. Ferrari, A. C. et al. Raman spectrum of graphene and graphene layers. *Phys. Rev. Lett.*, https://doi.org/10.1103/PhysRevLett.97.187401 (2006).

36. Kim, S.-G., Park, O.-K., Lee, J. H. & Ku, B.-C. Layer-by-layer assembled graphene oxide films and barrier properties of thermally reduced graphene oxide membranes. *Carbon Lett.* **14**, 247–250 (2013).

37. Vecera, P. et al. Degree of functionalisation dependence of individual Raman intensities in covalent graphene derivatives. *Sci. Rep.*, https://doi.org/10.1038/srep45165 (2017).

38. Myshakina, N. S., Ahmed, Z. & Asher, S. A. Dependence of Amide Vibrations on Hydrogen Bonding. *J. Phys Chem B* **112**, 11873–11877 (2009).

39. Gallagher, W. FTIR Analysis of Protein Structure. *Nature* **18**, 662–666 (1958).

40. Johansson, A., Kollman, P., Rothenberg, S. & McKelvey, J. Hydrogen Bonding Ability of the Amide Group. *J. Am. Chem. Soc.* **96**, 3794–3800 (1974).

41. Palladino, P., Minunni, M. & Scarano, S. Cardiac Troponin T capture and detection in real-time via epitope-imprinted polymer and optical biosensing. *Biosens. Bioelectron.* **106**, 93–98 (2018).

42. Subbiah, D. K., Nesakumar, N., Kulandaisamy, A. J. & Rayappan, J. B. B. Ferricyanide/reduced graphene oxide as electron mediator for the electrochemical detection of methanol in canned citrus sinensis and citrus limetta. *Sensors Actuators, B Chem.* **248**, 708–717 (2017).
Acknowledgements
Authors are grateful to Nano Mission Council (SR/NM/TP-83/2016(G)) and SERB (ECR/2016/001805), Department of Science & Technology for their financial support. We are grateful to SASTRA Deemed University for providing infrastructure support.

Author contributions
J.B.B.R. designed the hypothesis, analysis, supervision and drafted the manuscript; N.N. synthesised GQDs and analysed the data; M.L. synthesised and characterized the fGQDs, performed the electrochemical studies, interpreted sensing mechanism and drafted the manuscript writing; U.M.K. analysed the electrochemical data; K.S.R. performed the characterization analysis and manuscript revision; S.S. analysed the final version of the manuscript and supervised overall research work.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-53979-5.

Correspondence and requests for materials should be addressed to J.B.B.R.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019